# Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation

> **NCT04673175** · PHASE4 · TERMINATED · sponsor: **Weill Medical College of Cornell University** · enrollment: 17 (actual)

## Conditions studied

- Pneumonia
- Hematologic Malignancy
- Pseudomonas Aeruginosa Infection
- Bacteremia
- Hematopoietic Stem Cell Transplant (HSCT)

## Interventions

- **DRUG:** Ceftolozane / Tazobactam Injection

## Key facts

- **NCT ID:** NCT04673175
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-01-10
- **Primary completion:** 2025-03-16
- **Final completion:** 2025-03-16
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Due to slow accrual.
- **Last updated:** 2026-01-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04673175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04673175, "Ceftolozane-Tazobactam for Directed Treatment of Pseudomonas Aeruginosa Bacteremia and Pneumonia in Patients With Hematological Malignancies and Hematopoietic Stem Cell Transplantation". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04673175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*